Press Releases Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
10.65 ^USD	-6.91%		-13.77%	-26.65%

02/05	Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	North American Morning Briefing : Powell Awaited -2-	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights	03/05	GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	02/05	GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	02/04	AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	02/04	GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219	01/04	GL
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219	01/04	AQ
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights	01/04	GL
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle	07/03	AQ
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function	06/03	GL
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	04/03	AQ
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	02/03	GL
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference	09/01	GL
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study with BMF-219	09/01	AQ
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219	08/01	GL
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity in First Complete Responder from Ongoing Phase I Study of BMF-219 in Patients with Relapsed or Refractory Acute Myeloid Leukemia	12/12	AQ
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks off Treatment in Ongoing Phase II Study of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation	11/12	AQ
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	11/12	AQ
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting	11/12	GL
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts	10/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Press Releases

Filters